Halozyme Therapeutics, Inc. share price logo

Halozyme Therapeutics, Inc. Share Price

NASDAQ: HALO

Mid Cap

$63.27

-0.38

(-0.60%)

as on

Halozyme Therapeutics, Inc. Stock Performance

as on March 20, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $62.63
    $64.37
    downward going graph

    1.01%

    Downside

    1.74%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $47.50
    $82.22
    downward going graph

    24.92%

    Downside

    29.95%

    Upside

    downward going graph

Halozyme Therapeutics, Inc. share price movements today

Previous Close
$63.65
Open
$63.33
Volume
1.0M
Day's Low - High
$62.63 - $64.37
52 Week Low - High
$47.50 - $82.22

Halozyme Therapeutics, Inc. Historical Returns

1 Month Return
-10.86 %
3 Month Return
-6.06 %
1 Year Return
-1.63 %
3 Year Return
+ 81.71 %
5 Year Return
+ 43.37 %

Halozyme Therapeutics, Inc. Stock Fundamentals & Key Indicators

Check Halozyme Therapeutics, Inc. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$7.5B

EPS (TTM)

8.016

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.36%

PE Ratio (TTM)

24.86

Industry PE ratio

7.891681415929203

PEG Ratio

-2.5

EBITDA

897.8M

Revenue (TTM)

1.4B

Profit Margin

22.69%

Return On Equity TTM

153.59%

Halozyme Therapeutics, Inc. Stock Valuation

Track how Halozyme Therapeutics, Inc. P/E has moved over time to understand its valuation trends.

Halozyme Therapeutics, Inc. in the last 5 years

  • Overview

  • Trends

Lowest (10.98x)

June 30, 2025

Industry (7.89x)

March 20, 2026

Today (24.86x)

March 20, 2026

Highest (34.85x)

March 31, 2021

LowHigh

Today’s Price to Earnings Ratio: 24.86x

Halozyme Therapeutics, Inc. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Halozyme Therapeutics, Inc. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
Halozyme Therapeutics, Inc. image
Halozyme Therapeutics, Inc.
BUY$7.5B43.37%24.8622.69%
Alnylam Pharmaceuticals, Inc. image
Alnylam Pharmaceuticals, Inc.
BUY$41.7B115.8%135.118.45%
Vertex Pharmaceuticals Incorporated image
Vertex Pharmaceuticals Incorporated
BUY$114.7B111.95%29.532.94%
Beone Medicines Ltd image
Beone Medicines Ltd
NA$32.4BNA114.755.37%
Regeneron Pharmaceuticals, Inc. image
Regeneron Pharmaceuticals, Inc.
BUY$78.7B55.68%17.9531.41%

Stock Returns calculator for Halozyme Therapeutics, Inc. Stock including INR - Dollar returns

The Halozyme Therapeutics, Inc. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Halozyme Therapeutics, Inc. investment value today

Current value as on today

₹1,06,330

Returns

₹6,330

(+6.33%)

Returns from Halozyme Therapeutics, Inc. Stock

₹1,632 (-1.63%)

Dollar Returns*

₹7,962 (+7.96%)

Analyst Recommendation on Halozyme Therapeutics, Inc. Stock

Based on 17 analysts

BUY

82.35%

Buy

17.65%

Hold

0.00%

Sell

Based on 17 analysts, 82.35% of analysts recommend a 'BUY' rating for Halozyme Therapeutics, Inc.. Average target price of $84.5

Halozyme Therapeutics, Inc. Share Price Target

Get share price movements and forecasts by analysts on Halozyme Therapeutics, Inc..

What analysts predicted

25.12%UPSIDE

Target Price

$84.5

Current Price

$63.27

Analyzed by

17 Analysts

Target

$84.50

Halozyme Therapeutics, Inc. target price $84.5, a slight upside of 25.12% compared to current price of $63.27. According to 17 analysts rating.

Halozyme Therapeutics, Inc. Stock’s Investor Sentiment and Interest

Search interest for Halozyme Therapeutics, Inc. Stock has decreased by -30% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-30% versus previous 30 day period

Halozyme Therapeutics, Inc. Quarterly Profit & Loss

All numbers in Millions USD

Sep 2023
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
216
230
195
231
290
298
264
325
354
451
Gross Profit
161
177
149
173
240
255
216
279
299
349
Operating Income
88
101
95
117
163
175
141
202
217
254
EBITDA
129
127
115
137
190
203
168
229
284
281
Interest Expense
4
5
4
4
4
4
4
4
4
4
Depreciation
20
20
20
20
20
20
20
20
20
26
Income Before Tax
101
101
96
117
165
178
143
204
218
-100
Income Tax Expense
19
15
19
24
28
41
25
39
43
40
Net Income
81
85
76
93
137
137
118
165
175
-141
Net Profit Margin
37.88%
37.12%
39.22%
40.30%
47.23%
45.98%
44.59%
50.71%
49.46%
-31.34%

Halozyme Therapeutics, Inc. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
146
316
151
195
267
443
660
829
1,015
1,396
Gross Profit
113
285
141
150
224
361
520
636
855
1,091
Operating Income
-83
81
-69
-67
144
275
267
337
551
816
EBITDA
-80
83
-66
-63
147
278
315
451
656
904
Interest Expense
19
21
18
11
20
7
16
18
18
18
Depreciation
-
2
2
4
3
2
49
84
81
88
Income Before Tax
-101
61
-79
-72
129
248
248
348
557
466
Income Tax Expense
1
-1
0
0
0
-154
46
66
113
149
Net Income
-103
62
-80
-72
129
402
202
281
444
316
Net Profit Margin
-70.23%
19.89%
-52.90%
-36.86%
48.24%
90.84%
30.62%
33.96%
43.74%
22.69%

Halozyme Therapeutics, Inc. Quarterly Cash Flow

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Net Income
85
76
93
137
137
118
165
175
-141
Operating Cash Flow
102
129
55
115
178
154
99
178
219
Investing Cash Flow
-8
-82
-42
-167
29
-90
84
201
-741
Financing Cash Flow
-249
0
9
18
-246
-3
-298
-22
239
Change in Cash
-155
46
23
-33
-38
60
-114
357
-285

Halozyme Therapeutics, Inc. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
62
-80
-72
129
402
202
281
444
316
Operating Cash Flow
134
-49
-85
55
299
240
388
479
651
Investing Cash Flow
-163
2
-5
78
-406
-487
-96
-262
-545
Financing Cash Flow
131
-63
153
-106
77
362
-407
-218
-85
Change in Cash
101
-110
62
27
-28
115
-116
-2
20

Global Institutional Holdings in Halozyme Therapeutics, Inc.

Funds
Holdings
Royal London Asset Management Ltd
1.16%
Geode Capital Management, LLC
2.06%
Goldman Sachs Group Inc
1.17%
Snyder Capital Management LP
2.03%
Bank of America Corp
1.67%
See all

Halozyme Therapeutics, Inc. News & Key Events

    Insights on Halozyme Therapeutics, Inc.

    Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

    • imgPOSITIVE IMPACT

      Price Rise

      img

      In the last 3 years, HALO stock has moved up by 81.7%

    • imgPOSITIVE IMPACT

      Revenue Rich

      img

      Revenue is up for the last 4 quarters, 264.86M → 451.76M (in $), with an average increase of 16.1% per quarter

    • imgPOSITIVE IMPACT

      Best in 3 Years

      img

      In the last 3 years, HALO has outperformed top 5 stocks with highest market-cap in its industry

    • imgNO EFFECT

      Against Peers

      img

      In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 22.7% return, outperforming this stock by 24.3%

    • imgNEGATIVE IMPACT

      Profit Down

      img

      Netprofit is down for the last 2 quarters, 175.22M → -141.59M (in $), with an average decrease of 180.8% per quarter

    About Halozyme Therapeutics, Inc.

    we are a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapies that target the tumor microenvironment. our lead proprietary program, investigational drug pegph20, applies a unique approach to targeting solid tumors, potentially providing increased tumor access for co-administered cancer therapies. by breaking down potential barriers to cancer, pegph20 may help make existing treatments more effective by allowing therapies to reach the tumor. we are built on a foundation of value-driving partnerships with leading pharmaceutical companies including, roche, pfizer, janssen, baxalta, abbvie and lilly, for our enhanze™ drug delivery technology platform, which enables biologics and small molecule compounds currently administered intravenously to be delivered subcutaneously. this technology may also allow for more rapid delivery of therapies that are already delivered subcutaneously. we are a diverse team, who are committed to bringing therapies
    OrganisationHalozyme Therapeutics, Inc.
    Headquarters12390 El Camino Real, San Diego, CA, United States, 92130
    IndustryHealth Technology
    CEODr. Helen I. Torley M.B. Ch. B., M.R.C.P.
    E-voting on sharesClick here to vote

    Key Management of Halozyme Therapeutics, Inc.

    Name

    Title

    Ms. Nicole LaBrosse CPA

    Senior VP & CFO

    Mr. Mark Snyder Esq.

    Senior VP, General Counsel, Chief Compliance Officer & nd Secretary

    Mr. Paul Spence

    Chief Commercial Officer

    Mr. Chase Coffman Ph.D.

    President of Hypercon

    Dr. Charles P. Theuer M.D., Ph.D.

    Chief Medical Officer

    Mr. Rhys de Callier

    Chief Strategy Officer

    Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.

    President, CEO & Director

    Ms. Cortney Caudill M.B.A.

    Senior VP & COO

    Ms. Tram Bui

    Head of Investor Relations & Corporate Communications

    Dr. Christopher Wahl M.B.A., M.D.

    Chief Scientific Officer

    FAQs

    What is Halozyme Therapeutics, Inc. share price today?

    Halozyme Therapeutics, Inc. share price today is $63.27 as on at the close of the market. Halozyme Therapeutics, Inc. share today touched a day high of $64.37 and a low of $62.63.

    What is the 52 week high and 52 week low for Halozyme Therapeutics, Inc. share?

    Halozyme Therapeutics, Inc. share touched a 52 week high of $82.22 on and a 52 week low of $47.5 on . Halozyme Therapeutics, Inc. stock price today i.e. is closed at $63.27,which is 23.05% down from its 52 week high and 33.20% up from its 52 week low.

    What is Halozyme Therapeutics, Inc.'s market capitalisation today?

    Halozyme Therapeutics, Inc. market capitalisation is $0.01T as on .

    How to invest in Halozyme Therapeutics, Inc. Stock (HALO) from India?

    1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
    2. Step 2: Search for Halozyme Therapeutics, Inc. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Halozyme Therapeutics, Inc. Shares that will get you 0.0237 shares as per Halozyme Therapeutics, Inc. share price of $63.27 per share as on March 20, 2026 at 1:29 am IST.

    What is the minimum amount required to buy Halozyme Therapeutics, Inc. Stock (HALO) from India?

    Indian investors can start investing in Halozyme Therapeutics, Inc. (HALO) shares with as little as ₹93.193 or $1 (as of ) using the INDmoney app.
    For example: If you want to invest $10 or ₹931.93 in Halozyme Therapeutics, Inc. stock (as per the Rupee-Dollar exchange rate as on ). Based on Halozyme Therapeutics, Inc. share’s latest price of $63.27 as on March 20, 2026 at 1:29 am IST, you will get 0.1581 shares of Halozyme Therapeutics, Inc.. Learn more about fractional shares .

    What are the returns that Halozyme Therapeutics, Inc. has given to Indian investors in the last 5 years?

    Halozyme Therapeutics, Inc. stock has given 43.37% share price returns and 27.41% dollar appreciation to an Indian investor in the last 5 years.
    Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?